Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CENTRE FOR CANCER BIOMEDICINE ANNUAL REPORT 2007 CENTRE FOR CANCER BIOMEDICINE 2 TABLE OF CONTENTS SUMMARY .............................................................................................................................. 3 SCIENTIFIC ACTIVITY REPORT..................................................................................... 4 PRIZES, AWARDS and PROMOTIONS......................................................................... 8 MEDIA COVERAGE ........................................................................................................... 12 CCB PUBLICATIONS ........................................................................................................ 13 PRESENTATIONS .............................................................................................................. 16 ABOUT CCB......................................................................................................................... 17 PERSONNEL AND RECRUITMENT ............................................................................... 18 FUNDING AND COSTS.................................................................................................... 21 CENTRE FOR CANCER BIOMEDICINE 3 SUMMARY Centre for Cancer Biomedicine (CCB) was officially opened on 1st September 2007. Dedicated to the unification of basic and translational cancer research, the main asset of this centre, but also its most important challenge, is the seamless collaboration across the disciplines of cell biology, translational cancer research and biostatistics. Therefore, during the opening phase of the centre, much effort has been put into the planning and implementation of joint activities such as joint thematic seminars and interdisciplinary research projects. A centre webpage has also been established (www.ccb.uio.no). While the outcome of these efforts in terms of publications should become evident in a couple of years, it is clear that they are already having a positive impact on the scientific activity within the centre. Even though CCB has only been running for a few months, several important CCB papers have already been published. These include mechanistic insight into autophagy (“self-eating”), a cellular process that may have both tumour suppressive and tumour promoting functions, and the identification of a novel prospective biomarker for colorectal cancer, MAL. That CCB scientists are highly ranked among their peers is illustrated by several awards in 2007, including honorary doctorships to Kirsten Sandvig and Sjur Olsnes, the award of H.M. King Olav’s prize for excellent cancer research to Ragnhild Lothe, the award of Medinnova’s innovation prize to Ragnhild Lothe, Guro Elisabeth Lind, Rolf Skotheim and Terje Ahlquist, and the award of the Mørk’s legazy prize to Anne Simonsen. The first M.Sc. and Ph.D. candidates have graduated from CCB already, Ellen Røyrvik and Karine Lindmo. In conclusion, CCB got a head start in 2007, and there is a lot of enthusiasm to drive the successful execution of the centre project in the years to come. Drosophila eye disk Drosophila egg chamber CENTRE FOR CANCER BIOMEDICINE 4 SCIENTIFIC ACTIVITY REPORT 2007 Centre for Cancer Biomedicine (CCB) was officially opened on 1st September 2007. However, the scientific work of the centre was initiated as soon as the centre status was announced. In this report, publications listing CCB as affiliation are included even if some of these were published prior to 1st September. As many as 25 papers in international journals were published by CCB last year, demonstrating a high activity in the centre’s founding year. Although interdisciplinary collaborations lie at the heart of the centre project, it is clear that it will require some time to develop and consolidate such collaborations, and the publications arising from these will only appear in a couple of years’ time. In the meantime, it is pleasing to observe that the individual groups of CCB are involved in high-quality cancer research. Lothe’s group performs genetic and epigenetic studies of colorectal cancer, testis cancer, malignant peripheral nerve sheath tumours and prostate cancer. This group is already providing promising biomarkers for cancer (see below). Danielsen’s group uses genetics and advanced imaging to study prostate cancer, and to improve its diagnostics. Smeland’s group studies lymphomas and lymphocytes using both cell biological and genetic methods. Olsnes’ group has detected a novel mode of signalling by fibroblast growth factors and is interested in such signalling in the context of carcinogenesis. Sandvig’s group studies intracellular transport mechanisms in cells and more specifically how protein toxins enter cells, with the goal of understanding cancer and improving treatment. Stenmark’s group focuses on autophagy and endocytic downregulation of growth factor receptors, and the importance of these mechanisms in tumour suppression. Liestøl’s group develops novel biostatistical methods and applies them to study data from population studies, gene expression analyses and molecular imaging. While the research of the individual groups has been proceeding well, as documented by the list of publications, the vision of CCB is to generate an added value through novel collaborations across the disciplines of translational cancer research, biostatistics and cell biology. During the centre’s founding year, several such collaborations have been initiated, which will hopefully yield results of significance for cancer research and diagnostics within a few years. One of the highlights from last year was the identification of the MAL gene as a prospective biomarker for early detection of colorectal cancer (Lind et al, Gastroenterology, 2007). Promoter hypermethylation of MAL was shown to be present in the vast majority of colorectal adenomas and carcinomas and only rarely in normal mucosa. This places MAL as a promising early diagnostic marker, and further studies within CCB will not only validate the utility of MAL as a diagnostic marker but also seek to clarify the functions of MAL and their possible relevance to oncogenesis. Moreover, the methodology used to identify hypermethylation of MAL will be used to screen for additional prospective biomarkers in colorectal cancer as well as other cancers focused by the centre. CENTRE FOR CANCER BIOMEDICINE 5 One of the CCB-focused cancers, lymphoma, arises from lymphocytes, and a key activity in the centre will be to identify biomarkers that distinguish lymphoma cells from normal lymphocytes. In this context it is important to characterize gene expression patterns during normal lymphocyte development. CCB researchers have now characterized the early stages of human B lymphocyte development by gene expression profiling (Hystad et al., J.Immunol. 2007). Hierarchical clustering of 758 differentially expressed genes clearly separated hemopoietic stem cells, early B, pro-B, preB, and immature B cells. In future research at CCB, comparison of gene expression profiles of normal and neoplastic B cell progenitors may identify genes involved in the oncogenic transformation and gene products of potential prognostic and therapeutic relevance. Two membrane trafficking pathways, endocytosis and autophagy, are of special interest in cancer research. Endocytosis mediates downregulation of growth factor receptors, thereby potentially serving a tumour suppressor function. Autophagy serves to degrade damaged organelles, including those producing DNA-damaging oxygen radicals, and therefore has a tumour suppressor function. On the other hand, autophagy may also enable tumours to survive by providing them a source of amino acids. Recent research at CCB has shed light on the molecular mechanisms of both endocytic receptor downregulation and autophagy. In fact, CCB scientists were able to show that these two pathways interact (Rusten et al., Curr.Biol. 2007), a finding that was highlighted under “Leading Edge” in Cell. In future work it will be interesting to investigate possible correlations between the endocytic and autophagic machineries and oncogenesis, taking advantage of the multidisciplinary expertise of the centre. CCB scientists have also been active in writing reviews and commentary articles in 2007. Of special interest is a review article on aberrant receptor signalling and trafficking as mechanisms in oncogenesis (Haglund et al., Crit.Rev.Oncogen. 2007), since this review is very relevant to the prospective collaborative projects of CCB. Recent commentaries in leading journals (Rusten and Stenmark, Nature, 2007; Simonsen and Stenmark, Nat.Chem.Biol., 2007) have served to discuss novel aspects of autophagy and receptor trafficking, but have also contributed to place CCB on the cancer research map. In conclusion, even though CCB still is in its infancy, the scientific activity within the centre is already at an advanced level, and several projects stand out as promising areas for collaborative efforts. A key challenge in the years to come will be to improve the scientific standard even further by utilizing the potential represented by the complementary expertise of the centre scientists. CENTRE FOR CANCER BIOMEDICINE 6 EDUCATION AND INTERACTION ACTIVITY The scientific work of the centre was initiated as soon as the centre status was announced in January 2007. So were the centre activities, directed towards the unification of basic and translational cancer research and interdisciplinary research projects. These efforts of 2007 were manifested in the below list of seminars. CCB kick-off seminar at Soria Moria, May 7th-8th This was primarily a teambuilding seminar, with focus on the main goals of CCB CCB research programmes presentations by the group leaders group work on how to define and approach the challenges of CCB CoE experience by CMBN (Centre for Molecular Biology and Neuroscience), Tonje Tønnum Intellectual property rights, by Harald Dugstad, Medinnova social gathering The seminar was very successful in increasing the spirits and the consciousness of CCBs aims and vision. Scientists within the centre, but from different disciplines got to know each other better. The speakers, as well as the audience, were very enthusiastic when presenting and discussing CCB matters! From top left: Harald Stenmark/Chema Bassols, Maria Lyngaas Torgersen, Tonje Tønnum, Knut Liestøl, CCB, CCB and Sjur Olsnes/Håkon Wæhre. CENTRE FOR CANCER BIOMEDICINE 7 Start-up seminar and establishment celebration, November 9th at Hotel Plaza. This was a lunch seminar, taking CCB one step further against practical implementation of actions discussed in the previous seminar (Soria Moria). CCBs speakers as well as ‘actors’ got the chance to expose their innovative talents! From top left: Ragnhild Lothe (1st and 2nd picture), Harald Stenmark. CCB audience and CCB ubiquitin ‘actors’. Thematical seminars CCB started in 2007 an internal seminar series with primarily two purposes; One to stimulate interrelationships between people from different research groups by arranging the seminars together, and the other pure educational. The first seminar was held on December 10th on the theme: Colorectal cancers; disease, tumour etiology, clinical and biomedical challenges. The series has continued with monthly seminars in 2008. CENTRE FOR CANCER BIOMEDICINE 8 PRIZES, AWARDS and PROMOTIONS Medinnova's Idea Prize to CCB research group working on early markers for tumors in the digestive system Every year Medinnova distributes its Idea prize to the best idea with commercial potential originating from employees belonging to the Norwegian Health Region South-East (Helse SørØst). This years prize went to four employees from the Department of Cancer Prevention, Centre for Cancer Biomedicine (photo): Rolf I. Skotheim, Terje Ahlquist, Guro E. Lind and Ragnhild A. Lothe. They have identified new biological markers for colorectal tumours. These markers may contribute to the development of a test for discovering cancer at an early stage. Dr. Ragnar Mørk legacy prize to Anne Simonsen This year's prize from "Dr. Ragnar Mørk legacy" was awarded Anne Simonsen from the Department of Biochemistry, Centre for Cancer Biomedicine, at the Norwegian Radium Hospital. The "Dr. Ragnar Mørk legacy" prize is distributed annually to a scientist who has achieved excellent results throughout years of outstanding research. The ceremony took place in the seminar room at the Institute for Cancer Research on Friday 22nd of November. Simonsen gave a lecture summarizing her work. CENTRE FOR CANCER BIOMEDICINE 9 Centre of Cancer Biomedicine group leader, Sjur Olsnes, promoted honorary doctor at the Moscow Medical Academy Sjur Olsnes was in 2007 appointed honorary doctor at the Sechenov Academy in Moscow. He received the honor for his contributions to Russian medical research. His activities include establishing a centre for medical studies, as well as encouraging scientific cooperation between Russian and Norwegian research groups. The Sechenov Academy is the largest and oldest medical university in Moscow, as well as in Russia. Sjur Olsnes and Frode Lærum have cooperated with the Sechenov Academy since 1993. Activites they have introduced include exchange of students, supplementary training for medical doctors through joint seminars with Norwegian and Russian physicians, and supporting research of common interest. A close contact between the medical faculty at the University of Oslo and the Sechenov academy has developed through the years. Olsnes and Lærum have created a Centre for Medical Studies in Moscow, a place with competent offices and good infrastructure. The centre supports a number of research fellows, and is working for establishing contact with Norwegian research groups, with a view to scientific cooperation Centre of Cancer Biomedicine group leader, Kirsten Sandvig, promoted honorary doctor at The University of Copenhagen Kirsten Sandvig was Nov. 15th promoted honorary doctor at the Medical Faculty, University of Copenhagen (Doctor Medicinae Honoris Causa). The promotion took place at the annual Commemoration Ceremony of the University. HRH Queen Margrethe II and HRH Prince Henrik were both present and greeted the honorary doctors. The ceremony was followed by a reception and a gala performance of La Boheme in the Copenhagen Opera House. The main reasons for the appointment were that Kirsten Sandvig has been important for the scientific activity at the University of Copenhagen and that she has published more than 200 articles, many in high impact journals. Kirsten Sandvig has been collaborating with Bo van Deurs at the University of Copenhagen since 1984, and the collaboration has Kirsten resulted in more than 90 articles. ceremony Sandvig at the Among the scientific contributions is the early evidence for several endocytic pathways and the CENTRE FOR CANCER BIOMEDICINE 10 discovery of retrograde transport from the cell surface to the Golgi and the endoplasmic reticulum, published in Nature. Sandvig has been visiting Copenhagen in connection with courses, meetings and seminars, for instance in connection with the “Cell Biology Cluster” headed by Bo van Deurs. One reason for the appointment was that the collaboration has been of great importance for many young investigators at the University of Copenhagen. Several members of the Danish research group have been on longer visits to Sandvigs lab in Oslo. Rolf I. Skotheim appointed visiting professor in Finland Rolf I. Skotheim from the Department of Cancer Prevention at the Institute for Cancer Research has received a visiting professorship from the VTT Technical Research Centre of Finland. VTT is part of the "Translational Genome-Scale Biology" consortium, which is a Finnish Centre of Excellence, led by professor Olli Kallioniemi. Skotheim's new professorship strengthens the long-term collaboration between his own department - which is part of the Norwegian CoE "Centre for Cancer Biomedicine" - and the one of Olli Kallioniemi, as well as the collaboration between the two CoEs. Skotheim will mainly work together with a bioinformatics team, and one particular project concerns construction and utilization of a database of genome-wide transcriptome data from thousands of human samples. Careful biological and clinical annotation as well as normalization across the whole sample spectrum makes this a unique resource in the cancer research field. Rolf I. Skotheim has a PhD in cancer genetics and hands on experience in large-scale functional genomics. He is currently leading two major projects at the Department of Cancer Prevention “Qualitative transcript variation in solid tumours” and “Functional genomics of testicular germ cell tumours”. King Olav V’s prize for cancer research 2007 awarded to Centre of Cancer Biomedicine group leader, Ragnhild A. Lothe King Olav V's annual prize for cancer research 2007 was on June 14th awarded to Professor Ragnhild A. Lothe from the Department of Cancer Prevention, Centre for Cancer Biomedicine at the Institute for Cancer Research, Rikshospitalet HF. King Harald V presented Professor Lothe with this prestigious prize, which is funded by Norwegian Cancer Society. Ragnhild A. Lothe was recognized for her studies on the genetics and epigenetics of human solid tumours, with special emphasis on colorectal cancer, testicular cancer, and peripheral nerve sheath tumours. To CENTRE FOR CANCER BIOMEDICINE 11 gain knowledge of the complex dynamics of cancer development her research team has combined large-scale and detailed biology research using in vitro models and clinical samples. Lothe's goal is to bring the obtained information into molecularly assisted diagnostics, which ultimately may be useful for therapeutic decision-making. Professor Ragnhild Lothe was in 2007 also elected new member of ‘The Norwegian academy of Science and Letters’ Most of the above text in this section is copied from the webpage of Institute for Cancer Research at the Radium hospital; radium.no. CENTRE FOR CANCER BIOMEDICINE 12 MEDIA COVERAGE Some papers published by CCB researchers got special attention in 2007: Editorial in Cell highlights paper from Rusten and co-workers, Centre for Cancer Biomedicine. The December 28 issue of "Cell" (impact factor 29.19) had an editorial about autophagy. Here, recent important publications that had contributed to our understanding of this process - by identifying new molecular players and new ways to manipulate autophagic pathways - were discussed. Among these was an article from Tor Erik Rusten and co-workers, entitled "ESCRTs and Fab1 regulate distinct steps of autophagy". (from the ingress:) "The cellular process of autophagy (literally self-eating) is important during development and in the normal physiology of an organism. During autophagy, cellular components destined for degradation are enclosed in a double-membraned vesicle (the autophagosome), which then fuses with a lysosome where the contents are degraded and mostly recycled. Dysregulation of autophagy occurs in many diseases including cancer and neurodegeneration. Several recent papers contribute to our understanding of autophagy by identifying new molecular players in this process and new ways to manipulate autophagic pathways." Autophagy paper from ICR researchers highlighted in Science A recent paper from Anne Simonsen and co-workers published in the journal Autophagy (impact factor 6,7) - showing that induction of autophagy in the neurons of aging flies strongly increases their life span - was dedicated an editorial ("Editor's choice") in the 14th December issue of Science. Simonsen is the leader of the project group "Autophagy in health and disease" at Centre for Cancer Biomedicine, Institute for Cancer Research (ICR). Tor Erik Rusten and Pauline Isakson in good spirits and working hard! Most of the above text in this section is copied from the webpage of Institute for Cancer Research at the Radium hospital; radium.no. CENTRE FOR CANCER BIOMEDICINE 13 Articles on the announcement of Centre of Cancer Biomedicine as Centre of Excellence: An article about the Minister of Knowledge visiting Harald Stenmark at Institute of Cancer Research was published on Uniforum nett on Dec. 21st 2006. The CCB vision was cited. Link: http://wo.uio.no/as/WebObjects/avis.woa/wa/visArtikkel?id=34645&del=uniforum An article was published on Uniforum nett in March 2007. It is based on an interview of Harald Stenmark and Ragnhild Lothe who describe CCB, its vision, aims and challenges. Link: http://wo.uio.no/as/WebObjects/avis.woa/wa/visArtikkel?id=36485&del=uniforum RCN published in September an article in their journal ‘Forskning’ (no. 3/2007), about CCB cancer research. Link: http://forskningsradet.ravn.no/bibliotek/forskning/200703/2007030016.html CCB PUBLICATIONS 2007 Lind, G. E. Skotheim, R. I. Lothe, R. A. (2007) The epigenome of testicular germ cell tumors Apmis 115:1147-60 Nilsen T, Rosendal KR, S¸rensen V, Wesche J, Olsnes S, Wiedùocha A. A nuclear export sequence located on a beta-strand in fibroblast growth factor-1. J Biol Chem. 2007 Sep 7;282(36):26245-56. Sivertsen, E. A. Huse, K. Hystad, M. E. Kersten, C. Smeland, E. B. Myklebust, J. H. (2007) Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells Eur J Immunol 37:2937-48 Progida, C. Malerod, L. Stuffers, S. Brech, A. Bucci, C. Stenmark, H. (2007) RILP is required for the proper morphology and function of late endosomes J Cell Sci 120:3729-37 Hystad, M. E. Myklebust, J. H. Bo, T. H. Sivertsen, E. A. Rian, E. Forfang, L. Munthe, E. Rosenwald, A. Chiorazzi, M. Jonassen, I. Staudt, L. M. Smeland, E. B. (2007) Characterization of early stages of human B cell development by gene expression profiling J Immunol 179:3662-71 Haglund, K. Rusten, T. E. Stenmark, H. (2007) Aberrant receptor signaling and trafficking as mechanisms in oncogenesis Crit Rev Oncog 13:39-74 Spilsberg, B. Llorente, A. Sandvig, K. (2007) Polyunsaturated fatty acids regulate Shiga toxin transport Biochem Biophys Res Commun 364:283-8 CENTRE FOR CANCER BIOMEDICINE 14 Martin-Acebes, M. A. Gonzalez-Magaldi, M. Sandvig, K. Sobrino, F. Armas-Portela, R. (2007) Productive entry of type C foot-and-mouth disease virus into susceptible cultured cells requires clathrin and is dependent on the presence of plasma membrane cholesterol Virology 369:105-18 Pradhan M, Abeler VM, Danielsen HE, Risberg B. (2007) A distinct pattern in the DNA ploidy histograms of hydatidiform moles and nonmolar abortuses is caused by accumulation of trophoblasts in the late s-phase. Int J Gynecol Pathol. Oct;26(4):432-6. Kurmanova A, Llorente A, Polesskaya A, Garred O, Olsnes S, Kozlov J, Sandvig K. (2007) Structural requirements for furin-induced cleavage and activation of Shiga toxin. Biochem Biophys Res Commun. 2007 May 25;357(1):144-9. Llorente A, van Deurs B, Sandvig K. (2007) Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. Eur J Cell Biol. Jul;86(7):405-15. Utskarpen A, Slagsvold HH, Dyve AB, Skånland SS, Sandvig K. (2007) SNX1 and SNX2 mediate retrograde transport of Shiga toxin. Biochem Biophys Res Commun. Jun 29;358(2):566-70. Rusten TE, Stenmark H. (2007) Developmental biology: moonlighting at the pole. Nature. Feb 1;445(7127):497-9. Simonsen A, Stenmark H. Stimulating the cell's appetite for itself. Nat Chem Biol. 2007 Jun;3(6):304-6. Maler¸d L, Stuffers S, Brech A, Stenmark H. Vps22/EAP30 in ESCRT-II mediates endosomal sorting of growth factor and chemokine receptors destined for lysosomal degradation. Traffic. 2007 Nov;8(11):1617-29. Epub 2007 Aug 20. Rusten TE, Vaccari T, Lindmo K, Rodahl LM, Nezis IP, Sem-Jacobsen C, Wendler F, Vincent JP, Brech A, Bilder D, Stenmark H. ESCRTs and Fab1 regulate distinct steps of autophagy. Curr Biol. 2007 Oct 23;17(20):1817-25. Epub 2007 Oct 11. Almstrup K, Leffers H, Lothe RA, Skakkebaek NE, Sonne SB, Nielsen JE, Rajpert-De Meyts E, Skotheim RI. Improved gene expression signature of testicular carcinoma in situ. Int J Androl. 2007 Aug;30(4):292-302; discussion 303. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007 Feb 2;6:12. Lind GE, Ahlquist T, Lothe RA. DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632. Oldenburg J, Kraggerud SM, Bryd¸y M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-stransferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007 Dec 27;5:70. Royrvik EC, Ahlquist T, Rognes T, Lothe RA. Slip Slidin' Away: A Duodecen-nial Review of Targeted Genes in Mismatch Repair Deficient Colorectal Cancer. Crit Rev Oncog. 2007;13(3):229-57. CENTRE FOR CANCER BIOMEDICINE 15 Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z. The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers. Epigenetics. 2007 Oct-Dec;2(4):237-43. . Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007 Jul 10;6:45. Simonsen A., Cumming R. and Finley K.D. Linking lysosomal trafficking defects with changes in aging and stress response in Drosophila. Autophagy, 2007; Sep-Oct;3(5):499-501 Simonsen A., Cumming RC., Lindmo K., Galavis V., Cheng S., Rusten TE. and Finley K.D. Genetic modifiers of the Drosophila blue cheese gene link defects in lysosomal transport with decreased life span and altered ubiquitinated-protein profiles. Genetics. 2007; 176(2) 1283-1297 Coworkers of Centre for Cancer Biomedicine in action. CENTRE FOR CANCER BIOMEDICINE 16 PRESENTATIONS Some international meetings where CCB participants have presented their work: Harald Stenmark: Chairman and speaker at the subgroup meeting on “Ubiqutin as a regulator of membrane trafficking”, ELSO congress, Dresden, Germany. (1-4.9.07) Invited speaker and meeting vice chair of the EMBO conference on “Membrane Dynamics in Endocytosis”, Villars, Switzerland. (18-23.09.07) Invited speaker at the International Symposium on Membrane Trafficking, Awajishima, Japan. (27-30.11.07) Ragnhild Lothe: Invited Speaker at Oncological Forum in Bergen (20-21.11.07) Kirsten Sandvig: Invited speaker at University of Kuopio, Finland, (29-31.10.07). Lecture: entry of protein toxins into cells. CENTRE FOR CANCER BIOMEDICINE 17 ABOUT CCB Organization Centre for Cancer Biomedicine (CCB) at the University of Oslo (UiO) and Rikshospitalet HF has since st September 1 2007 been a Centre of Excellence, appointed by the Research Council of Norway. The centre is located at the Radium hospital, Rikshospitalet HF. CCB is a constellation of 7 independent research groups cooperating to reach the aims of the centre. The groups are headed by, respectively, the group leaders Harald Stenmark, Ragnhild Lothe, Sjur Olsnes, Kirsten Sandvig, Erlend Smeland, Håvard Danielsen and Knut Liestøl/Ole Crisitian Lingjærde. Management CCB is headed by Harald Stenmark (director) and Ragnhild A. Lothe (vice director). Stenmark has the daily responsibility for project management, administration and delivery (technical and financial), assisted by administrative coordinator, Jannikke Ludt. The director collaborates closely with the Executive Group, consisting of the additional six Principal Investigators, in scientific matters. Lothe assists Stenmark in scientific matters and strategy and represents CCB in the Stenmark’s absence. Board The centre management reports to the centre board. The board was not constituted until 2008, but the members are: Sigbjørn Fossum (UiO), chair Anders Elverhøi (UiO) Karl-Erik Giercksky (Rikshospitalet HF) Erlend Smeland (Rikshospitalet HF) International advisory board An international advisory board for scientific matters will be appointed in 2008. University of Oslo Rikshospitalet Institute for Cancer Research Faculty division Radiumhospit Faculty of Medicine The Research Council of Norway Faculty of Mat. Nat. CENTRE BOARD International advisory board CENTRE MANAGEMENTT Executive group (7 group leaders) CENTRE FOR CANCER BIOMEDICINE 18 PERSONNEL AND RECRUITMENT The centre is staffed by 94 persons, of whom 63 (67%) are women. When categorized by position, the profile is 7 group leaders, 11 researchers (senior scientists), 23 post docs and 29 PhD students. Technical and Administrative staff are 24 persons. Total staff 35 Number of persons 30 25 20 15 10 5 st ud en Te ts ch n/ Ad m .S ta ff Ph D do cs Po st es ea rc he rs R G ro up le ad er s 0 The persons participating in Centre for Cancer Biomedicine in 2007 were (blue print: Funded by the CCB grant): List of CCB employees, 2007 Name Position Group Ahlquist, Terje Alagaratnam, Sharmini Andersson, Sofia Bakkebø, Maren PhD student Postdoc, Lothe Lothe Norway Malaysia RHF from 12.11.07 Rikshospitalet HF MSc PhD Postdoc Stipendiat, Sandvig Smeland Sweden Norway Rikshospitalet HF Rikshospitalet HF PhD MSc Bassols, Chema Computer specialist PhD student Technician Olsnes Spania Rikshospitalet HF Lothe Olsnes Norway Norway Rikshospitalet HF Rikshospitalet HF MSc Project Leader, Senior Scientist (FUGE) PhD student Professor / Group Leader Research fellow Stenmark Norway Rikshospitalet HF PhD Lothe Danielsen Norway Norway Rikshospitalet HF Rikshospitalet HF MSc PhD Lothe Norway Rikshospitalet HF MSc Ph.D. Student (RCN) Ph.D student Sandvig Norway Rikshospitalet HF MSc Smeland Norway UiO MD Forsker Medical technologist Postdoc Lothe Lothe Norway Norway Rikshospitalet HF Rikshospitalet HF PhD Sandvig Norway Rikshospitalet HF PhD Technician Olsnes Norway Rikshospitalet HF Berg, Marianne Bergersen, Anne Gro Brech, Andreas Brekke, Helge Danielsen, Håvard Danielsen, Stine Aske Dyve, Anne Berit Eide, Marianne Brodtkorb Eiken, Hans Geir Eknæs, Mette Engedal, Kim Nikolai Engen, Anne Nationality Employer Academic title CENTRE FOR CANCER BIOMEDICINE Farstad, Benedikte Filimonenko, Maria Forfang, Lise Guha, Nirmalendu Haglund, Kaisa Haugsten, Ellen M. Heggland, Grete Hektoen, Merete Hilden, Vera Irene Homeide Aagesen, Trude Huse, Kanutte Hveem, Tarjei Sveinsgjerd Isakson, Pauline Iversen, ToreGeir Jin, Yi-xin Johannessen, May Elisabeth Kildahl, Wanja Kjæreng, Marna Lill Kolberg, Matthias Kraggerud, Sigrid M. Lauvrak, Silje Anett Ugland Lemus, Dafne Liestøl, Knut Lind, Guro Elisabeth Lindmo, Karine Lindvall, Jessica Lingjærde, Ole Christian Lobert, Viola Lothe, Ragnhild A. Ludt, Jannikke Løvig, Tone Malecki, Jedrzej Malerød, Lene Merok, Marianne Aarstad Mjøen, Linda Uv Myklebust, June Helen Myrann, Anne Grethe Nesheim, John Arne Nezis, Ioannis Nielsen, Birgitte Nilsgård, Siri 19 Technician (CCB) Stenmark Norway Rikshospitalet HF Ph.D. student (University of Oslo) Technician, Laboratory assistant Postdoc (Human Frontier Science Programme) Ph.D. student Stenmark Norway UiO Smeland Olsnes Norway Norway Rikshospitalet HF Rikshospitalet HF Bachelor Stenmark Sweden Human Frontier Science program PhD Olsnes Norway Rikshospitalet HF MSc Technician Medical technologist Technician PhD student Sandvig Lothe Norway Norway Rikshospitalet HF Rikshospitalet HF MSc Smeland Lothe Norway Norway Rikshospitalet HF Rikshospitalet HF MSc MSc PhD student Developer Smeland Danielsen Norway Norway Rikshospitalet HF Rikshospitalet HF MSc MSc Ph.D. student (FUGE) Senior Scientist (RCN) Post doc Secretary Stenmark Sweden Rikshospitalet HF MSc Sandvig Norway Rikshospitalet HF PhD Olsnes Olsnes China Norway Rikshospitalet HF Rikshospitalet HF PhD Ph. D student Danielsen Danielsen Norway Norway Rikshospitalet HF Rikshospitalet HF MSc Researcher Post doc Lothe Lothe Norway Norway Rikshospitalet HF Rikshospitalet HF PhD PhD Postdoc (Norw. Cancer Soc.) Ph.D. student Professor / Group Leader Post doc Sandvig Norway Rikshospitalet HF PhD Stenmark Liestøl Mexico Norway Rikshospitalet HF UiO MSc PhD. Lothe Norway Rikshospitalet HF PhD Ph.D. student (CCB) Post doc Førsteamanuensis Stenmark Norway Rikshospitalet HF PhD Liestøl Liestøl Sweden Norway UiO UiO PhD PhD Technician (the Norwegian Cancer Society) Professor / Group Leader Administrative coordinator, Medical technologist Guest Senior Scientist (Norw. Cancer Soc.) Postdoc (FUGE) PhD student Stenmark France Rikshospitalet HF Lothe Norway Rikshospitalet HF PhD Norway UiO PhD Lothe Norway Rikshospitalet HF PhD Olsnes Poland Rikshospitalet HF PhD Stenmark Lothe Norway Norway Rikshospitalet HF Aker / RH PhD MD Post doc Smeland Norway Norway Rikshospitalet HF Rikshospitalet HF PhD Technician Sandvig Norway Rikshospitalet HF Developer Danielsen Norway Rikshospitalet HF Postdoc (FUGE) Post doc Laboratory Stenmark Danielsen Olsnes Greece Norway Norway Rikshospitalet HF Rikshospitalet HF Rikshospitalet HF MSc PhD PhD CENTRE FOR CANCER BIOMEDICINE Oksvold, Morten Olsnes, Sjur Pedersen, Nina Marie Pretorius, Maria Pust, Sascha Raiborg, Camilla Ribeiro, Franclim Ricardo da Silva Rodahl, Lina W. Roxrud, Ingrid Rusten, Tor Erik Rødland, Einar Rønning, Eva Røyrvik, Ellen C. Raa, Hilde Sagona, Antonia Sandvig, Kirsten Sem-Jacobsen, Catherine Simonsen, Anne Skiple Skjerpen, Camilla Skotheim, Rolf I. Skånland, Sigrid Slåtta, Carina Smeland, Erlend Bremertun Stenmark, Harald Stordal Bjørklund, Sunniva Maria Stuffers, Susanne Sveen, Anita Sørensen, Vigdis Tengs, Torstein Tolonen Egeberg, Nina Johanna Torgersen, Maria Lyngaas Utskarpen, Audrun Wesche, Jørgen Wiedlocha, Antoni Wæhre, Håkon Yadollahi, Mandana Zakrzewska, Malgorzata Zhen, Yan 20 assistant Post doc Group leader, Professor, dr.med. Postdoc (Helse Sør) Ph.D student Postdoc Postdoc (the Norwegian Cancer Society) Post doc Smeland Olsnes Norway Norway Rikshospitalet HF Rikshospitalet HF PhD MD, PhD Stenmark Norway Rikshospitalet HF PhD Danielsen Sandvig Stenmark Norway Germany Norway Rikshospitalet HF Rikshospitalet HF Rikshospitalet HF MSc PhD PhD Lothe Portugal Ph.D. student (EMBIO) Ph.D. student (RCN) Postdoc (FUGE) Post doc Head technician Research fellow Ph.D. student Ph.D. student (EU) Professor / Group Leader PhD student (the Norwegian Cancer Society) Project Leader, Senior Scientist (the Norwegian Cancer Society) Post doc Stenmark Norway UiO MSc Stenmark Norway Rikshospitalet HF MSc Stenmark Liestøl Stenmark Lothe Sandvig Stenmark Norway Norway Norway Norway Norway Norway Rikshospitalet NR Rikshospitalet Rikshospitalet Rikshospitalet Rikshospitalet PhD PhD HF HF HF HF MSc MSc MSc Sandvig Norway Rikshospitalet HF PhD Stenmark Norway Rikshospitalet HF MSc Stenmark Norway Rikshospitalet HF PhD Olsnes Norway Rikshospitalet HF PhD Project leader, senior scientist Ph.D. student Laboratory Assistant Professor / Group Leader Professor / Group Leader Ph.D. student Lothe Norway Rikshospitalet HF PhD Sandvig Olsnes Norway Norway Rikshospitalet HF Rikshospitalet HF MSc Smeland Norway Rikshospitalet HF MD, PhD Stenmark Norway UiO PhD Olsnes Norway Rikshospitalet HF MSc PhD student (FUGE) PhD student Post doc Post doc Technician (FUGE) Postdoc Stenmark Norway Rikshospitalet HF MSc Lothe Olsnes Danielsen Stenmark Norway Norway Norway Finland Rikshospitalet Rikshospitalet Rikshospitalet Rikshospitalet HF HF HF HF MSc PhD PhD Sandvig Norway Rikshospitalet HF PhD Ph.D. student Sandvig Norway Rikshospitalet HF MSc Project Leader, Senior Scientist (Norw. Cancer Soc.) Project Leader, Senior Scientist Senior scientist Laboratory Assistant Post doc Olsnes Norway Rikshospitalet HF PhD Olsnes Norway Rikshospitalet HF PhD Danielsen Olsnes Norway Rikshospitalet HF Rikshospitalet HF MD, PhD Olsnes Norway Rikshospitalet HF PhD Ph.D. student Olsnes Norway PhD HF MSc CENTRE FOR CANCER BIOMEDICINE 21 FUNDING AND COSTS The total income of CCB from Sept 1st 2007 was 21 744 thousand NOK. The funding was distributed on different sources, as the chart indicates. Own funding covers support from the host institution (UiO) and the consortium participant Rikshospitalet HF, and includes salary, location and running costs. CoE funding is the CCB funding provided by Research Council of Norway (3401 kNOK) Other funding is from public and private CCB sources, including FUGE and grants from The Norwegian Cancer society. TOTAL FUNDING 2007 X 1000 NOK 12000 9298 9045 10000 8000 6000 3401 4000 2000 0 Own funding CoE funding Other public/private The total costs for CCB during the four months from Sept. 1st were 20 520 kNOK. Salary, including social costs contributed to this with 14 351 kNOK. Indirect costs include premises and infrastructure and were estimated to 5 715 kNOK. 2 172 kNOK were invested in scientific equipment. EXPENDITURES X 1000 NOK 20000 15000 14351 10000 5715 5000 2172 424 0 Salary Indirect Equipment Running costs CENTRE FOR CANCER BIOMEDICINE 22 CCB Centre for Cancer Biomedicine Norwegian Radium hospital Montebello N-0310 Oslo Phone: +47 22934292 [email protected] www.ccb.uio.no